Type 2 Diabetes
Conditions
Brief summary
This is a randomized, double-blind, placebo-controlled Phase Ib/IIa clinical study in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise and/or treated with irregular use of antidiabetic drugs to evaluate the safety, tolerability, pharmacokinetics and efficacy of GZR18 injection in adult subjects with T2DM. This study is divided into Part A and Part B, which are to be conducted simultaneously.
Interventions
OTHERPlacebo
administered the same volume as GZR18
DRUGGZR18
0.5mg-13mg
Sponsors
Gan and Lee Pharmaceuticals, USA
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Chinese adults, male and female, aged 18-65 years (both inclusive; subject to the date of signing of ICF). 2. Diagnosis of type 2 diabetes mellitus according to the diagnostic and classification criteria for diabetes mellitus issued by the World Health Organization (WHO) in 1999. 3. Patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise and/or treated with irregular use of antidiabetic drugs. 4. Hemoglobin A1c (HbA1c) ≥ 7.0% and ≤ 10 % at screening; 5. Body mass index (BMI) ≥ 18.5 kg/m2 and ≤ 35 kg/m2 at screening. 6. Those who have no birth and sperm donation plans, and voluntarily take effective contraceptive measures from the signing of ICF to 3 months after the last dose. A negative pregnancy test for women of childbearing potential at screening. 7. Fully understanding the study objectives, the nature of the study, methods used and adverse reactions that may occur in the study, willing to enter the study and sign the ICF, and capable of communicating well with the investigator, and understanding and abiding by the requirements of the study.
Exclusion criteria
1. Diabetes mellitus other than T2DM, such as type 1 diabetes mellitus. 2. Fasting C-peptide \< 0.3 nmol/L. 3. Use of any DPP-4 inhibitors, insulin secretagogues such as sulfonylureas, TZDs and/or GLP-1 analogs within 3 months prior to screening. 4. Continuous insulin use for more than 14 days within 1 year prior to screening (time of insulin use for gestational diabetes mellitus is excluded from this limit). 5. Treatment with growth hormone, diuretics, etc., that may affect insulin levels as judged by the investigator within 6 months prior to screening. 6. Immunoserologic panel test results \[infection screening tests for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), and Treponema pallidum antibody\] assessed by the investigator as abnormal and clinically significant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of adverse events and serious adverse events | 29 weeks |
| Changes from baseline in hemoglobin A1c (HbA1c) at the end of the study | 26 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Trough concentrations of GZR18 following consecutive doses | 26 weeks |
| HbA1c control rate (proportions of subjects with HbA1c < 6.5 % and HbA1c < 7.0 %) | 26 weeks |
Countries
China
Outcome results
None listed